Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery
In a retrospective cohort of 84 resected pulmonary invasive mucinous adenocarcinomas, next-generation sequencing was performed and genomic alterations were correlated with prognosis. KRAS was the predominant driver (∼68 %), and concurrent TP53 mutations (∼32 %) independently predicted worse overall and disease-free survival within KRAS-mutant IMA. TP53 co-mutation serves as a practical risk stratifier to inform closer post-surgical surveillance and potential adjuvant strategies.
Authors
- Dong Woog Yoon (ORCID: https://orcid.org/0000-0003-3845-9151)
- Yeong Jeong Jeon (ORCID: https://orcid.org/0000-0001-6745-6131)
- Jong Ho Cho (ORCID: https://orcid.org/0000-0003-3362-4621)
- Yong Soo Choi (ORCID: https://orcid.org/0000-0002-2552-0067)
- Hong Kwan Kim (ORCID: https://orcid.org/0000-0002-7815-3336)
- Byeong‐Ho Jeong (ORCID: https://orcid.org/0000-0002-3124-1718)
- Soohyun Hwang (ORCID: https://orcid.org/0000-0003-4581-3286)
- Dong Wook Shin (ORCID: https://orcid.org/0000-0001-8128-8920)
- Boram Lee (ORCID: https://orcid.org/0000-0002-7784-5971)
- Jung Hee Lee (ORCID: https://orcid.org/0000-0002-5070-8248)
- Sung Yong Park (ORCID: https://orcid.org/0000-0002-5180-3853)
Institutions
- Samsung Medical Center (KR)
- Kangbuk Samsung Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.101014
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00